← Back to all trials
Not Yet Recruiting
NCT07759245
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Conditions: Pulmonary Disease, Chronic Obstructive
Sex: All
Ages: 40 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 606
Sponsor: Eli Lilly and Company
Location: University of Alabama at Birmingham Birmingham Alabama
Summary
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Eligibility Criteria
Inclusion Criteria:
* Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria:
* Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years
* Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (\
Source: ClinicalTrials.gov (NCT07759245). StuddyBuddy aggregates publicly available trial information.
